These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11209988)

  • 41. Role of fibrinolytic markers in acute stroke.
    Abdullah WZ; Idris SZ; Bashkar S; Hassan R
    Singapore Med J; 2009 Jun; 50(6):604-9. PubMed ID: 19551314
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study.
    Crowther MA; Roberts J; Roberts R; Johnston M; Stevens P; Skingley P; Patrassi GM; Sartori MT; Hirsh J; Prandoni P; Weitz JI; Gent M; Ginsberg JS
    Thromb Haemost; 2001 Mar; 85(3):390-4. PubMed ID: 11307802
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Cardiovascular risk factors and prevention in women: similarities and differences].
    Sclavo M
    Ital Heart J Suppl; 2001 Feb; 2(2):125-41. PubMed ID: 11255880
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Platelet (dys)function and plasma plasminogen levels in hemodialysis patients.
    Salobir B; Sabovic M; Zupan IP; Ponikvar JB
    Ther Apher Dial; 2008 Apr; 12(2):133-6. PubMed ID: 18387161
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.
    Sebestjen M; Zegura B; Guzic-Salobir B; Keber I
    Wien Klin Wochenschr; 2001 Feb; 113(3-4):113-8. PubMed ID: 11253736
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic architecture of tissue-type plasminogen activator and plasminogen activator inhibitor-1.
    Asselbergs FW; Pattin K; Snieder H; Hillege HL; van Gilst WH; Moore JH
    Semin Thromb Hemost; 2008 Sep; 34(6):562-8. PubMed ID: 19085655
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hypofibrinolysis is a risk factor for arterial thrombosis at young age.
    Guimarães AH; de Bruijne EL; Lisman T; Dippel DW; Deckers JW; Poldermans D; Rijken DC; Leebeek FW
    Br J Haematol; 2009 Apr; 145(1):115-20. PubMed ID: 19183334
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Endothelium, thrombosis and fibrinolysis].
    Alessi MC; Juhan-Vague I
    Rev Prat; 1997 Dec; 47(20):2227-31. PubMed ID: 9616910
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epidemiology of thrombotic-hemostatic factors and their associations with cardiovascular disease.
    Pearson TA; LaCava J; Weil HF
    Am J Clin Nutr; 1997 May; 65(5 Suppl):1674S-1682S. PubMed ID: 9129509
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coagulative and fibrinolytic activity in parietal thrombus of aortic aneurysm.
    Gacko M; Worowska A; Głowiński S
    Rocz Akad Med Bialymst; 1999; 44():102-10. PubMed ID: 10697424
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease.
    Wiman B; Hamsten A
    Semin Thromb Hemost; 1990 Jul; 16(3):207-16. PubMed ID: 2146744
    [No Abstract]   [Full Text] [Related]  

  • 52. Acquired defects of fibrinolysis associated with thrombosis.
    Fareed J; Hoppensteadt DA; Jeske WP; Ahmad S; Bick RL
    Semin Thromb Hemost; 1999; 25(4):367-74. PubMed ID: 10548070
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fibrinolysis inhibitors.
    Davis GL
    Clin Lab Sci; 1997; 10(4):212-8. PubMed ID: 10169620
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plasminogen activator inhibitor-1: a common denominator in cardiovascular disease.
    Vaughan DE
    J Investig Med; 1998 Oct; 46(8):370-6. PubMed ID: 9805421
    [No Abstract]   [Full Text] [Related]  

  • 55. Endogenous Fibrinolysis: An Important Mediator of Thrombus Formation and Cardiovascular Risk.
    Okafor ON; Gorog DA
    J Am Coll Cardiol; 2015 Apr; 65(16):1683-1699. PubMed ID: 25908074
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of lipoprotein(a) with atherothrombotic events and fibrinolytic variables. A case-control study.
    Franceschini G; Cofrancesco E; Safa O; Boschetti C; Tremoli E; Mussoni L; Sirtori CR; Cortellaro M
    Thromb Res; 1995 May; 78(3):227-38. PubMed ID: 7631303
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Relationship between fibrinolytic system and neurological diseases].
    Zea M; Bermejo PE; Carrillo F
    Rev Neurol; 2010 Sep; 51(5):295-301. PubMed ID: 20669129
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The genetic component of coronary risk. II].
    Carluccio M; Vanuzzo D; Pilotto L; Fioretti P; Quadrifoglio F; Diviacco S; Mariani M; De Caterina R
    Cardiologia; 1999 Feb; 44(2):155-67. PubMed ID: 10208052
    [No Abstract]   [Full Text] [Related]  

  • 59. Exercise-induced changes in coagulation and fibrinolysis in healthy populations and patients with cardiovascular disease.
    Womack CJ; Nagelkirk PR; Coughlin AM
    Sports Med; 2003; 33(11):795-807. PubMed ID: 12959620
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Role of lipoprotein (a) in the development of atherosclerosis and formation of thrombi].
    Wandzilak M; Jodłowski J
    Pol Tyg Lek; 1991 Sep 9-30; 46(37-39):720-1. PubMed ID: 1669142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.